Aminocyclitols as pharmacological chaperones for glucocerebrosidase, a defective enzyme in Gaucher disease

ChemMedChem

Volumn 2, Issue 7, 2007, Pages 992-994

  Egido Gabás, Meritxell ^a   Canals, Daniel ^a   Casas, Josefina ^a   Llebaria, Amadeu ^a   Delgado, Antonio ^a,b  

^a DEPARTMENT OF ENVIRONMENTAL CHEMISTRY   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chaperones; Cyclitols; Gaucher; Glucocerebrosidase; Glycolipids

Indexed keywords

CHAPERONE; CYCLITOL; GLUCOSYLCERAMIDASE; UNCLASSIFIED DRUG;

ARTICLE; ENZYMOLOGY; GAUCHER DISEASE; GENETICS; HUMAN; METABOLISM; MUTATION; PROTEIN DENATURATION; SYNTHESIS;

CYCLITOLS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MOLECULAR CHAPERONES; MUTATION; PROTEIN DENATURATION;

EID: 34548540634     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200700061     Document Type: Article

References (30)

1. A. R. Sawkar, W. D'Haeze, J. W. Kelly, Cell. Mol. Life Sci. 2006, 63, 1179-1192.
2. T. Kolter, M. Wendeler, ChemBioChem 2003, 4, 260-264.
3. J.-P. Morello, M. Bouvier, U. E. Petaja-Repo, D. G. Bichet, Trends Pharmacol. Sci. 2000, 21, 466-469.
4. J.-Q. Fan, Trends Pharmacol. Sci. 2003, 24, 355-360.
5. T. D. Butters, Expert Opin. Pharmacother. 2007, 8, 427-435.
6. R. O. Brady, Bailliere's Clin. Anaesthesiol. 1997, 10, 621-634.
7. H. Zhao, G. A. Grabowski, Cell. Mol. Life Sci. 2002, 59, 694-707.
8. D. P. Germain, Clin. Genet. 2004, 65, 77-86.
9. R. H. Lachmann, Curr. Opin. Invest. Drugs 2003, 4, 472-479.
10. A. H. Futerman, J. L. Sussman, M. Horowitz, I. Silman, A. Zimran, Trends Pharmacol. Sci. 2004, 25, 147-151.
11. R. J. Desnick, E. H. Schuchman, Nat. Rev. Genet. 2002, 3, 954-966.
12. R. J. Desnick, J. Inherited Metab. Dis. 2004, 27, 385-410.
13. Isofagomine derivatives: a) H. H. Chang, N. Asano, S. Ishii, Y. Ichikawa, J. Q. Fan, FEBS J. 2006, 273, 4082-4092;
14. b) R. A. Steet, S. Chung, B. Wustman, A. Powe, H. Do, S. A. Kornfeld, Proc. Natl. Acad. Sci. USA 2006, 103, 13813-13818;
15. c) X. Zhu, K. A. Sheth, S. Li, H. H. Chang, J. Q. Fan, Angew. Chem. 2005, 117, 7616-7619;
16. Angew. Chem. Int. Ed. 2005, 44, 7450-7453;
17. Z. Yu, A. R. Sawkar, L. J. Whalen, C. H. Wong, J. W. Kelly, J. Med. Chem. 2007, 50, 94-100.
18. Deoxynojirimycin derivatives: d) P. Alfonso, S. Pampin, J. Estrada, J. C. Rodriguez-Rey, P. Giraldo, J. Sancho, M. Pocovi, Blood Cells Mol. Dis. 2005, 35, 268-276;
19. e) L. Yu, K. Ikeda, A. Kato, I. Adachi, G. Godin, P. Compain, O. Martin, N. Asano, Bioorg. Med. Chem. 2006, 14, 7736-7744;
20. f) see ref. [20]. Iminoxilitol derivatives: g) P. Compain, O. R. Martin, C. Boucheron, G. Godin, L. Yu, K. Ikeda, N. Asano, ChemBioChem 2006, 7, 1356-1359.
21. Aminocyclitol derivatives: h) H. Lin, Y. Sugimoto, Y. Ohsaki, H. Ninomiya, A. Oka, M. Taniguchi, H. Ida, Y. Eto, S. Ogawa, Y. Matsuzaki, M. Sawa, T. Inoue, K. Higaki, E. Nanba, K. Ohno, Y. Suzuki, Biochim. Biophys. Acta Mol. Basis Dis. 2004, 1689, 219-228.
22. M. Egido-Gabás, P. Serrano, J. Casas, A. Llebaria, A. Delgado, Org. Biomol. Chem. 2005, 3, 1195-1201.
23. P. Serrano, J. Casas, M. Zucco, G. Emeric, M. Egido-Gabás, A. Llebaria, A. Delgado, J. Comb. Chem. 2007, 9, 43-52.
24. P. Serrano, A. Llebaria, A. Delgado, J. Org. Chem. 2005, 70, 7829-7840.
25. Estimation of lipophilicity has been carried out according to Crippen's and Viswanadhan's fragmentation methods (A. K. Ghose, G. M. Gripen, J. Chem. Inf. Comput. Sci. 1987, 27, 21
26. and V. N. Viswanadhan, A. K. Ghose, G. R. Revankar, R. K. Robins, J. Chem. Inf. Comput. Sci. 1989, 29, 163, respectively) using the integrated module provided by the Chem-Draw Ultra 9.0 package (Cambridgesoft, 2004).
27. A similar correlation between chain length and GlucCerase inhibition has also been observed in isofagomine derivatives (ref [13c]) and iminoxilitol derivatives (ref [13g]). Likewise, this general trend has been observed in deoxynojirimycin derivatives on various glycosidases (G. Godin, P. Compain, O. R. Martin, K. Ikeda, L. Yu, N. Asano, Bioorg. Med. Chem. Lett. 2004, 14, 5991-5995).
28. i=2 nM, ref. [13g]). This last compound has been reported to double the residual activity in fibroblasts from Gaucher patients (ref. [13g]) at a concentration sensibly lower than that required for NNDNJ for a similar effect (ref. [14]).
29. A. R. Sawkar, W. C. Cheng, E. Beutler, C. H. Wong, W. E. Balch, J. W. Kelly, Proc. Natl. Acad. Sci. USA 2002, 99, 15428-15433.
30. V. Rotrekl, E. Nejedla, I. Kucera, F. Abdallah, K. Palme, B. Brzobohaty, Eur. J. Biochem. 1999, 266, 1056-1065.